Insitro has raised a total of $643 million across multiple funding rounds, with its largest being a $400 million Series C in March 2021. The South San Francisco-based biotech company uses machine learning and high-throughput biology to transform drug discovery and development. Its platform integrates in vitro and clinical data to accelerate therapeutic programs in metabolism, oncology, and neuroscience. Backed by investors like CPP Investments, Andreessen Horowitz, and BlackRock, Insitro is advancing AI-driven biology to reduce costs, improve outcomes, and streamline drug development pipelines.